AI Article Synopsis
- Chronic myelogenous leukemia (CML) is a type of blood cancer caused by a specific genetic mutation involving the BCR-ABL gene.
- Vincristine (VCR) is a common treatment for leukemia but often faces challenges due to multidrug resistance (MDR), limiting its effectiveness.
- Researchers developed a DNA nanoflower that can effectively deliver VCR and P-glycoprotein siRNA into CML cells, showing potential to overcome drug resistance and enhance treatment efficacy.
Article Abstract
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder caused by the BCR-ABL chimeric tyrosine kinase. Vincristine (VCR) is widely used in leukemia therapy but is hindered by multidrug resistance (MDR). We prepared DNA nanoflower via self-assembly for the delivery of VCR and P-glycoprotein small interfering RNA (P-gp siRNA). The as-prepared nanoflower had a floriform shape with high loading efficiency of VCR (80%). Furthermore, the nanoflower could deliver VCR and P-gp siRNA into MDR CML cells and induce potent cytotoxicity both and , thus overcoming MDR of CML. Overall, this nanoflower is a promising tool for resistant CML therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475561 | PMC |
| http://dx.doi.org/10.3389/fbioe.2023.1265199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!